<?xml version="1.0" encoding="UTF-8"?>
<p id="para0003">In an attempt to pre-empt the challenges arising from a narrow therapeutic window, chemoprophylaxis has been explored. Whereas several studies support that prophylactic administration of NAIs lowered the risk of developing disease,
 <xref rid="bib0008" ref-type="bibr">
  <sup>8</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0013" ref-type="bibr">
  <sup>13</sup>
 </xref> the CDC recommends reserving chemoprophylaxis for people in high risk groups and for outbreak control among high risk individuals in institutional settings.
 <xref rid="bib0014" ref-type="bibr">
  <sup>14</sup>
 </xref> In contrast, general chemoprophylaxis is not recommended due to the unclear risk-benefit for otherwise healthy patients and concerns of promoting the development of viral resistance.
</p>
